Rafferty Asset Management
BIO icon

Rafferty Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rafferty Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,212
Closed -$604K – 1148
2024
Q2 		$604K Buy
2,212
+56
+3% +$16.3K ﹤0.01% 911
2024
Q1 		$746K Buy
2,156
+29
+1% +$9.54K ﹤0.01% 880
2023
Q4 		$687K Sell
2,127
-52
-2% -$16.3K ﹤0.01% 896
2023
Q3 		$781K Buy
2,179
+91
+4% +$35.1K ﹤0.01% 852
2023
Q2 		$792K Buy
2,088
+165
+9% +$67.1K ﹤0.01% 872
2023
Q1 		$921K Buy
1,923
+79
+4% +$37K 0.01% 817
2022
Q4 		$775K Buy
1,844
+701
+61% +$283K 0.01% 812
2022
Q3 		$477K Buy
1,143
+618
+118% +$308K 0.01% 865
2022
Q2 		$260K Sell
525
-136
-21% -$70.8K ﹤0.01% 965
2022
Q1 		$372K Sell
661
-65
-9% -$39.2K ﹤0.01% 1072
2021
Q4 		$549K Buy
726
+41
+6% +$30.7K ﹤0.01% 1044
2021
Q3 		$511K Buy
685
+239
+54% +$179K ﹤0.01% 1036
2021
Q2 		$287K Buy
446
+22
+5% +$13.4K ﹤0.01% 1183
2021
Q1 		$242K Buy
424
+51
+14% +$30.2K ﹤0.01% 1120
2020
Q4 		$217K Sell
373
-1,329
-78% -$757K ﹤0.01% 967
2020
Q3 		$877K Buy
1,702
+1,220
+253% +$618K 0.01% 593
2020
Q2 		$218K Buy
+482
New +$213K ﹤0.01% 908
2017
Q3 		– Sell
-3,618
Closed -$819K – 595
2017
Q2 		$819K Buy
+3,618
New +$788K 0.02% 398

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rafferty Asset Management's BIO Position: Q3 2024 in Review

Rafferty Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 2,212 shares — an estimated $604K sold.

Rafferty Asset Management first reported a position in BIO in Q2 2017 and held it in 18 quarters. The position peaked at $921K in Q1 2023. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

  • Rafferty Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
  • Rafferty Asset Management sold 2,212 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $604K.
  • Rafferty Asset Management first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and held it in 18 quarters.
  • Rafferty Asset Management's Bio-Rad Laboratories Class A position peaked at $921K in Q1 2023.
  • 438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Rafferty Asset Management's 13F filing for Q3 2024, filed 13 Nov 2024.